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Abstract
Background: Use of inhaled corticosteroids (ICS) increases the risk of pneumonia in chronic obstructive pulmonary
disease (COPD), but the magnitude of risk with different ICS remains unclear.
Methods: A post hoc analysis of the 4-year UPLIFT® trial to assess whether pneumonia risk differed by type of ICS
(fluticasone propionate [FP], other ICS, or no ICS) in permanent users (defined by use until end of study) or in users
at baseline (sensitivity analysis).
Results: For the permanent-users analysis, 825 patients receiving FP throughout the trial, 825 patients receiving
other ICS and 825 patients not receiving ICS were matched on relevant baseline features 1:1:1. A significantly
greater risk of pneumonia was observed for FP versus no ICS: the hazard ratio (HR) for risk of pneumonia was
1.33 (95% confidence interval [CI] 1.00, 1.75; p = 0.046) and the rate ratio (RR) was 1.58 (95% CI 1.05, 2.37; p = 0.028).
A greater risk was also found for FP versus other ICS: HR 1.28 (95% CI 0.97, 1.68; p = 0.078) and RR 1.48 (95% CI 1.00, 2.19;
p = 0.049). A higher proportion of patients on FP were hospitalized with pneumonia (7.9%) versus other ICS (6.7%) or no
ICS (5.9%). Whilst other ICS use was associated with the highest number of fatal pneumonia events, the total number
of fatal pneumonia incidents was low. A similar pattern was observed in the sensitivity analyses, which included 4002
patients on different treatments at baseline (FP, other ICS, and no ICS) and considered potential switches during the
study.
Conclusion: The results support existing evidence of an increased pneumonia risk with FP use compared with other ICS
and no ICS use in patients with COPD. Healthcare professionals should evaluate the risk–benefit ratio of using ICS when
making treatment decisions with their patients.
Trial registration: Post hoc analysis of UPLIFT®. ClinicalTrials.gov number: NCT00144339. Retrospectively registered
September 2, 2005.
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Plain english summary
People with chronic obstructive pulmonary disease
(COPD) who take inhaled corticosteroids (ICS) have a
higher risk of pneumonia than those who don’t. How-
ever, it is not clear how big this risk is.
To help answer this question, we looked at findings
from UPLIFT®, a large study of patients with COPD. We
assessed whether ICS use affected pneumonia risk, and
whether different types of ICS (fluticasone propionate or
other types of ICS) had different effects. Unlike past inves-
tigations, we only included people who remained on the
same type of ICS for the whole study, and compared these
carefully to people who didn’t take any ICS but were
otherwise similar. Therefore, any change in the risk of
pneumonia was likely due to the ICS treatment rather
than other potential effects, such as differences in disease
severity between patients.
The results suggest that people taking fluticasone pro-
pionate have roughly 33% greater risk of pneumonia
compared with those not taking ICS. They also have a
28% greater risk compared with people taking other ICS.
Overall, this study agrees with the results of other
studies, and suggests that fluticasone propionate in-
creases the risk of pneumonia compared with other ICS
or no ICS in people with COPD. This is important be-
cause many people with COPD use fluticasone propi-
onate. This study can help doctors to decide on the
most appropriate treatment for people with COPD
who are at risk of pneumonia.
Background
Inhaled corticosteroids (ICS) are widely used for the
treatment of chronic obstructive pulmonary disease
(COPD) [1]. The Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) report currently positions ICS
in combination with bronchodilators as a second-line
option to reduce exacerbation rates in patients in GOLD
groups C and D who have experienced frequent exacerba-
tions [2]. Despite this, it has been estimated that more than
70% of patients with COPD are treated with high doses of
ICS, including those at low risk of exacerbations [3].
Recent randomized controlled trials suggest that ICS
can be discontinued in some patients with stable COPD
for whom ICS treatment may not be indicated without
compromising safety and efficacy [4]. Moreover, the
therapeutic benefits of widespread use of ICS remain
controversial [3, 5–11]. High doses potentially result in
systemic effects that could lead to glaucoma, cataracts,
adrenal suppression, osteoporosis, bone fractures, skin
bruising, and diabetes mellitus [4, 7, 8, 12–16].
While evidence for some of these adverse effects is
weak, there is strong support (mainly from large clinical
trials, population-based studies, and systematic reviews)
for a significant increase in the risk of pneumonia in
patients with COPD prescribed ICS (alone or in combin-
ation) [5, 6, 12, 17–24]. Published data in trials of up to
3 years in duration have shown an increased risk of
pneumonia associated with ICS therapy in patients with
COPD [19, 24, 25]. In light of this increased risk, it has
been suggested that the use of ICS therapy should be re-
stricted to the minority of patients with COPD who are
likely to be particularly responsive to ICS therapy and in
whom the benefits of treatment outweigh the risks [4]. Sev-
eral studies suggest that the magnitude of pneumonia risk
varies between types of ICS, with the greatest risk associ-
ated with fluticasone propionate (FP) [5, 6, 18, 22, 26].
However, there is conflicting evidence regarding the risk of
pneumonia associated with different types of ICS, and this
adds complexity when making treatment decisions [22, 27].
Interpretation of the clinical significance of many of
the previous analyses of pneumonia risk in COPD is lim-
ited by the fact that they are from short-term studies
[12] or that they only record the type of ICS use at base-
line [28], and thus do not provide information on pa-
tients who remain on ICS in the long term. However,
these issues can be overcome in subgroup analyses of
the 4-year Understanding Potential Long-term Impacts
on Function with Tiotropium (UPLIFT®) study, which
permitted inhaled ICS use during both the run-in and
treatment periods [29].
The UPLIFT® study included a large population of
patients with COPD over 4 years [29]. Reflecting a
close-to-real-life scenario, the patients were permitted to
continue using respiratory medications, with the excep-
tion of other anticholinergics. This provides a large data
set, in which we can investigate the effects of different
types of ICS and their prescribing patterns, and how this
relates to pneumonia outcomes. The initial study results
showed similar overall risk of pneumonia during treat-
ment with tiotropium 18 μg and placebo (risk 14.5% and
13.9%, respectively; relative risk [corrected for exposure]
0.96 [95% confidence interval (CI) 0.84, 1.10]) [29].
However, the original analysis of the study did not evalu-
ate the risk of pneumonia in the subgroup of patients re-
ceiving concomitant ICS versus those without ICS
throughout the duration of the trial, nor did it look at
the individual effects of FP. A previous retrospective
subgroup analysis of the UPLIFT® study data found that
incidence rates of pneumonia were significantly higher
in patients taking ICS, and that this increase was mainly
associated with patients using FP (versus other ICS) at
randomization [28]. However, this previous analysis had
an uneven distribution of baseline characteristics be-
tween subgroups, which made interpretation of the re-
sults difficult.
We conducted this current post hoc analysis of the
UPLIFT® study on pooled treatment groups to assess
whether the risk of pneumonia in UPLIFT® differed
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according to the type of ICS used (FP, other ICS, and no
ICS). We ran an analysis on matched subgroups of pa-
tients whom we know remained on the same ICS treat-
ment throughout the study (permanent users), and
repeated this type of analysis on the subgroups defined
by baseline ICS use alone (two sensitivity analyses: FP,
other ICS, and no ICS; and any ICS versus no ICS).
Methods
Study design and population
UPLIFT® was a 4-year, randomized, double-blind,
placebo-controlled, parallel-group trial involving 5993
patients with moderate-to-very severe COPD, random-
ized to either tiotropium (n = 2987) or placebo (n =
3006) [29]. The trial evaluated the impact of tiotropium
HandiHaler® 18 μg versus placebo on lung function,
quality of life, exacerbations, and mortality.
Patients had a confirmed diagnosis of COPD and were
aged ≥40 years, with a smoking history of ≥10 pack-years
and a post-bronchodilator forced expiratory volume in
1 s (FEV1) ≤70% of the predicted value and an FEV1 ≤
70% of forced vital capacity. Patients were excluded if
they had a recent severe cardiac event or unstable
COPD (exacerbation within 4 weeks), moderate or se-
vere renal impairment, or other significant lung diseases.
Pneumonia history was not assessed as an eligibility cri-
terion for the study. Patients were permitted to use their
usual background treatment for COPD (including ICS),
except for other inhaled anticholinergics. Medication
could be adjusted by the treating physician during the
4-year study duration; however, dose was not captured
at baseline or during the study. For this analysis, the
route of administration was derived from brand names
and indication for use.
Full details of the UPLIFT® methodology have been
published previously [29, 30].
Post hoc analysis of pneumonia events
This post hoc analysis included ICS-treated patients
matched with patients who had not received ICS during
the UPLIFT® trial. Pneumonia risk was derived from gen-
eral adverse event reports while patients were receiving a
study drug (up to and including the last day of a study
drug). Treatment arms were pooled for this analysis.
A diagnosis of pneumonia was determined by
investigator-reported adverse events based on evidence
of typical symptoms and clinical findings, together with
chest radiology (where available) and laboratory findings.
A mortality adjudication committee, comprised of mem-
bers external to the study sponsor and of those involved
in the conduct of the trial, adjudicated all reported
deaths in the UPLIFT® trial; this committee provided a
consistent, systematic, and independent assessment of
the primary cause of death (e.g. fatal pneumonia).
Statistical analysis
The study treatments – tiotropium and placebo – were
pooled for the analyses, as there was no difference in
risk of pneumonia between these treatment groups in
the original analyses [31].
For the initial analysis, patients were classified by type
of ICS use during the course of the study. Patients using
FP throughout the study period were classified as “per-
manent FP users”. Patients using ICS from baseline to
end of treatment (but not FP) were classified as “per-
manent users of other ICS” (mostly budesonide or beclo-
methasone). Patients in this “permanent users of other
ICS” group could switch between different types of ICS,
but not to FP or no ICS; 684 out of the 825 patients
(82.9%) in this group did not switch to nor added an-
other ICS. Those patients not taking any ICS during
the course of the study were classified as “permanent
no ICS users”.
A secondary sensitivity analysis was carried out on
subgroups defined by type of ICS use at baseline (FP,
other ICS, or no ICS); a third analysis investigated ICS
use (all types) versus no ICS use at baseline. Further-
more, the number of pneumonia events was also ana-
lyzed according to the type of ICS use (FP, other ICS, or
no ICS) reported at the last clinic visit before the first
pneumonia event. All the patients in these latter analyses
did not necessarily receive this background treatment
regimen for the entire duration of the trial.
In order to minimize potential bias caused by differ-
ences in baseline characteristics between subgroups, pa-
tients were matched in a 1:1:1 ratio using the following
baseline features: race, age (± 5 years), FEV1% predicted
(± 5% predicted), GOLD stage, emphysema diagnosis,
and antibiotic usage during the year prior to study start.
The triplets of patients were generated randomly until
no further matched triplets could be identified. Further
matching processes were conducted for use of FP, other
ICS or no ICS use at study baseline, and for ICS use ver-
sus no ICS use (secondary analyses).
For all analyses, Cox regression with matching factors
as covariates was used to calculate hazard ratios (HR)
and 95% CIs comparing time to first pneumonia, pneu-
monia requiring hospitalization, and pneumonia result-
ing in death between the matched subgroups. Annual
rates, rate ratios (RR), and respective 95% CIs were cal-
culated for pneumonia events and hospitalizations due
to pneumonia using a Poisson regression model with
matching factors as covariates.
Results
Analysis populations
Of the 5993 trial participants in the UPLIFT® study, a
total of 3700 (61.7%) patients were receiving ICS at base-
line. The first analyses of the matched subgroups of
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permanent users comprised 2475 patients (825 perman-
ent FP users, 825 permanent users of other ICS, and 825
no ICS users). In the second analyses, which evaluated
patients by type of ICS use at baseline, 4002 patients
were matched, with 1334 patients per subgroup (FP,
other ICS, and no ICS). Finally, 3948 patients were in-
cluded in the analysis of any ICS versus no ICS use at
baseline, with 1974 in each matched subgroup.
The demographic and baseline characteristics of the
first two sets of matched subgroups – permanent users
and users at baseline – are shown in Table 1. Corre-
sponding data for the third analyses (patients receiving
ICS versus no ICS at baseline) are provided in the data
supplement (Additional file 1: Table S1). Baseline char-
acteristics of the subgroups, including weight, height,
and body mass index (BMI), were generally similar. The
average age was approximately 65 years among the pa-
tients, and three-quarters of participants were male. Pa-
tients were mostly overweight (BMI > 25 kg/m2) and
approximately one-third were current smokers. There
was a higher proportion of current smokers in the per-
manent and baseline no-ICS groups than in the other
groups. Over half of the patients had severe (GOLD
Stage III) or very severe (GOLD Stage IV) COPD. There
was also a lower proportion of patients receiving anti-
cholinergics at baseline in the permanent and baseline
no-ICS groups than in the other groups.
Risk of pneumonia
Permanent-user analysis
The results of the first analysis show that the time to
first pneumonia was shorter and the rate of pneumonia
(per patient-year) was greater in permanent users of FP
compared with no ICS (HR 1.33 [95% CI 1.00, 1.75; p =
0.046] and RR 1.58 [95% CI 1.05, 2.37; p = 0.028], re-
spectively) and compared with other ICS (HR 1.28 [95%
CI 0.97, 1.68; p = 0.078] and RR 1.48 [95% CI 1.00, 2.19;
p = 0.049], respectively; Table 2). However, HRs and RRs
of pneumonia events did not differ between permanent
Table 1 Baseline characteristics of patients in matched subgroups by type of ICS use
Permanent users Use at baseline
FP
(n = 825)
Other ICS
(n = 825)
No ICS
(n = 825)
FP
(n = 1334)
Other ICS
(n = 1334)
No ICS
(n = 1334)
Male, n (%) 570 (69.1) 620 (75.2) 624 (75.6) 942 (70.6) 1014 (76.0) 996 (74.7)
Age, years, mean (SD) 65.0 (8.0) 64.9 (8.0) 64.8 (7.8) 64.9 (8.0) 64.9 (7.9) 64.8 (7.8)
Height, cm, mean (SD) 169.81 (9.2) 169.71 (8.6) 170.30 (8.5) 169.52 (9.0) 169.79 (8.4) 169.85 (8.7)
Weight, kg, mean (SD) 77.82 (16.7) 75.09 (15.9) 76.08 (18.1) 76.87 (16.7) 75.41 (16.3) 75.78 (17.9)
Body mass index, kg/m2, mean (SD) 26.89 (5.0) 25.97 (4.6) 26.10 (5.3) 26.65 (5.0) 26.05 (4.8) 26.15 (5.4)
Race, n (%)
White 808 (97.9) 808 (97.9) 808 (97.9) 1291 (96.8) 1291 (96.8) 1291 (96.8)
Black – – – 1 (0.1) 1 (0.1) 1 (0.1)
Asian 17 (2.1) 17 (2.1) 17 (2.1) 42 (3.1) 42 (3.1) 42 (3.1)
Current smoker, n (%) 191 (23.2) 216 (26.2) 298 (36.1) 316 (23.7) 347 (26.0) 473 (35.5)
Non-inhaled steroid use, n (%) 83 (10.1) 78 (9.5) 52 (6.3) 129 (9.7) 114 (8.5) 74 (5.5)
Anticholinergic use, n (%) 422 (51.2) 372 (45.1) 308 (37.3) 692 (51.9) 637 (47.8) 542 (40.6)
GOLD stage, n (%)
II 395 (47.9) 395 (47.9) 395 (47.9) 621 (46.6) 621 (46.6) 621 (46.6)
III 371 (45.0) 371 (45.0) 371 (45.0) 608 (45.6) 608 (45.6) 608 (45.6)
IV 59 (7.2) 59 (7.2) 59 (7.2) 105 (7.9) 105 (7.9) 105 (7.9)
FEV1, L, mean (SD) 1.11 (0.4) 1.12 (0.4) 1.13 (0.4) 1.09 (0.4) 1.10 (0.4) 1.10 (0.4)
FEV1, % predicted, mean (SD) 39.72 (11.4) 39.80 (11.5) 39.78 (11.4) 39.14 (11.5) 39.10 (11.4) 39.17 (11.4)
FVC, L, mean (SD) 2.67 (0.9) 2.70 (0.8) 2.65 (0.8) 2.63 (0.9) 2.67 (0.8) 2.62 (0.8)
FVC, % predicted, mean (SD) 76.20 (18.6) 75.88 (17.4) 73.65 (17.0) 74.99 (18.2) 74.91 (17.5) 73.68 (17.4)
FEV1/FVC, mean (SD) 0.42 (0.1) 0.42 (0.1) 0.43 (0.1) 0.42 (0.1) 0.42 (0.1) 0.43 (0.1)
Post-bronchodilator FEV1, L, mean (SD) 1.34 (0.4) 1.35 (0.4) 1.37 (0.4) 1.32 (0.4) 1.33 (0.4) 1.34 (0.4)
Post-bronchodilator FEV1, % predicted, mean (SD) 48.06 (12.1) 47.90 (12.1) 48.09 (12.0) 47.62 (12.3) 47.30 (12.3) 47.68 (12.4)
Abbreviations: FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease,
ICS inhaled corticosteroid, SD standard deviation. Patients within each group were matched by race, age (± 5 years), FEV1% predicted (± 5% predicted), GOLD stage,
emphysema diagnosis, and courses of antibiotics during the previous year
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users who received other ICS and patients who received
no ICS (Table 2; Fig. 1a).
The risk of hospitalized pneumonia, based on time to
first pneumonia hospitalization, was also greater in per-
manent users of FP treatment compared with other ICS
and no ICS (Fig. 2). A numerically higher proportion of
permanent FP users was hospitalized with pneumonia
events (7.9%) compared with patients treated with no
ICS (5.9%) or other ICS (6.7%; Table 2). Based on small
patient numbers, a numerically higher proportion of pa-
tients receiving other ICS (n = 13, 1.58%) had fatal pneu-
monia events than those receiving no ICS (n = 9, 1.09%)
or users of FP (n = 7, 0.85%) (Table 2).
Matched-subgroups analysis by type of ICS use at baseline
A similar pattern was observed in this second analysis,
which evaluated patients according to their ICS use at the
start of the study. Patients treated with FP at baseline had
an increased risk of pneumonia, in terms of time to event,
versus patients not on ICS (HR 1.30 [95% CI 1.06, 1.59; p =
0.012]; Table 3), with a 20% higher risk with FP than for
other ICS (HR 1.20 [95% CI 0.99, 1.47; p = 0.067]; Table 3;
Fig. 1b). Likewise, the annual rate of pneumonia was high-
est in patients receiving FP versus no ICS (RR 1.37 [95% CI
1.06, 1.78; p = 0.015]) or other ICS (RR 1.35 [95% CI
1.05, 1.74; p = 0.020]) at baseline (Table 3). Only minor dif-
ferences were observed between pneumonia events in pa-
tients on other ICS and those on no ICS (Table 3; Fig. 1b).
A higher proportion of patients treated with FP at base-
line was hospitalized with pneumonia events (10.5%) com-
pared with patients receiving no ICS (7.5%) or on other
ICS (8.5%) at baseline. The risk of hospitalization due to
pneumonia was greater in patients treated with FP at
baseline compared with no ICS (HR 1.48 [95% CI 1.14,
1.91; p = 0.003] and RR 1.46 [95% CI 1.07, 1.98; p = 0.016],
respectively) or other ICS (HR 1.31 [95% CI 1.02, 1.68; p
= 0.032] and RR 1.34 [95% CI 0.99,1.81; p = 0.055], re-
spectively). The HR and RR of hospitalized pneumonia
events were slightly increased for other ICS versus no ICS
use at baseline (Table 3). However, based on small patient
numbers, numerically more patients receiving other ICS
at baseline (n = 18, 1.35%) had fatal pneumonia events
than those receiving no ICS (n = 15, 1.12%) or FP (n = 8,
0.60%) at baseline (Table 3).
ICS therapy proximate to the first pneumonia event (last
visit before event)
As the UPLIFT® study allowed changes in the concomitant
therapy of the patients, pneumonia events were also ana-
lyzed according to the type of ICS use (FP, other ICS, or no
ICS) reported at the last clinic visit before the first pneumo-
nia event. Table 4 shows the percentage of patients with a
first pneumonia or hospitalized/fatal pneumonia event who
received FP, other ICS, or no ICS at baseline, and also de-
scribes the percentage who were on these treatments at the
last visit before the event occurred. All patients switching
Table 2 Risk of pneumonia by type of ICS in permanent users
Treatment throughout study Comparison
FP Other ICS No ICS FP versus other ICS
HR* or RR† (95% CI);
p-value
FP versus no ICS
HR* or RR† (95% CI);
p-value
Other ICS versus no ICS
HR* or RR† (95% CI);
p-value
Permanent users, n 825 825 825 – – –
Patients with pneumonia events, n (%)# 115 (13.9) 95 (11.5) 87 (10.5) HR 1.28
(0.97, 1.68);
p = 0.078
HR 1.33
(1.00, 1.75);
p = 0.046
HR 1.03
(0.77, 1.38);
p = 0.830
Pneumonia events, n 159 111 98 – – –
Adjusted rate of pneumonia events
(per patient-year), mean (95% CI)
0.10
(0.07, 0.14)
0.07
(0.04, 0.10)
0.06
(0.04, 0.10)
RR 1.48
(1.00, 2.19);
p = 0.049
RR 1.58
(1.05, 2.37);
p = 0.028
RR 1.07
(0.69, 1.65);
p = 0.773
Patients with hospitalized pneumonia
events, n (%)
65 (7.9) 55 (6.7) 49 (5.9) HR 1.24
(0.86, 1.77);
p = 0.249
HR 1.30
(0.90, 1.88);
p = 0.168
HR 1.05
(0.71, 1.54);
p = 0.802
Hospitalized pneumonia events, n 78 64 51 – – –
Adjusted rate of hospitalized pneumonia
events (per patient-year), mean (95% CI)
0.05
(0.03, 0.08)
0.04
(0.03, 0.07)
0.04
(0.02, 0.06)
RR 1.25
(0.78, 2.02);
p = 0.355
RR 1.47
(0.88, 2.44);
p = 0.141
RR 1.17
(0.69, 1.99);
p = 0.560
Patients with pneumonia resulting in
death, n (%)
7 (0.85) 13 (1.58) 9 (1.09) HR 0.54
(0.22, 1.36);
p = 0.194
HR 0.75
(0.28, 2.01);
p = 0.567
HR 1.38
(0.59, 3.23);
p = 0.460
Abbreviations: CI confidence interval, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, GOLD Global Initiative for Chronic Obstructive Lung Disease,
HR hazard ratio, ICS inhaled corticosteroid, RR rate ratio. Matched-subgroup population. *Cox regression analysis with ICS use on-treatment and matching factors
as covariates. †Poisson regression with ICS use on-treatment and matching factors (age, FEV1% predicted, GOLD stage, emphysema diagnosis, and courses of
antibiotics) as covariates. #In this analysis, 23 patients treated permanently with FP received the treatment for non-pulmonary (mostly nasal) indication only; three
of these patients had a pneumonia event during the study. In the subgroup permanently treated with other ICS, these numbers were 10 and 3, respectively
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Fig. 1 Time to first pneumonia in patients receiving ICS (FP, other, no): a) Permanent (b) Baseline. Abbreviations: FP: fluticasone propionate;
ICS: inhaled corticosteroid
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treatments prior to the event, as well as those who had no
pneumonia event and switched at any time during the
study, were counted in each respective group, thereby in-
creasing the denominator compared with the patients in
the baseline analysis so that all percentages are lower. Tak-
ing switches into account did not result in important
changes in the overall results. The relative pattern of the
frequency of pneumonia and hospitalized pneumonia
events according to treatment was maintained (Table 4).
Matched-pairs analysis by any ICS versus no ICS use at
baseline
Analyses based on patients treated with all types of ICS
versus no ICS at baseline are reported in the data
Fig. 2 Time to first pneumonia hospitalization by type of ICS (permanent users). Abbreviations: FP: fluticasone propionate; ICS: inhaled corticosteroid
Table 3 Risk of pneumonia by type of treatment (FP, other ICS, no ICS use) at baseline
Treatment at baseline Comparison
FP Other ICS No ICS FP versus other ICS
HR* or RR†
(95% CI);
p-value
FP versus no ICS
HR* or RR†
(95% CI);
p-value
Other ICS versus no ICS
HR* or RR†
(95% CI);
p-value
Use at baseline, n 1334 1334 1334 – – –
Patients with pneumonia event, n (%)# 207 (15.5) 184 (13.8) 169 (12.7) HR 1.20
(0.99, 1.47);
p = 0.067
HR 1.30
(1.06, 1.59);
p = 0.012
HR 1.08
(0.88, 1.33);
p = 0.467
Pneumonia events, n 286 220 214 – – –
Adjusted rate of pneumonia events
(per patient-year), mean (95% CI)
0.10
(0.08, 0.12)
0.07
(0.06, 0.09)
0.07
(0.05, 0.09)
RR 1.35
(1.05, 1.74);
p = 0.020
RR 1.37
(1.06, 1.78);
p = 0.015
RR 1.02
(0.77, 1.34);
p = 0.907
Patients with hospitalized pneumonia
events, n (%)
140 (10.5) 114 (8.5) 100 (7.5) HR 1.31
(1.02, 1.68);
p = 0.032
HR 1.48
(1.14, 1.91);
p = 0.003
HR 1.13
(0.86, 1.47);
p = 0.382
Hospitalized pneumonia events, n 172 133 121 – – –
Adjusted rate of hospitalized pneumonia
events (per patient-year), mean (95% CI)
0.06
(0.04, 0.08)
0.04
(0.03, 0.06)
0.04
(0.03, 0.05)
RR 1.34
(0.99, 1.81);
p = 0.055
RR 1.46
(1.07, 1.98);
p = 0.016
RR 1.09
(0.79, 1.51);
p = 0.607
Patients with pneumonia resulting in
death, n (%)
8 (0.60) 18 (1.35) 15 (1.12) HR 0.46
(0.20, 1.05);
p = 0.066
HR 0.55
(0.23, 1.30);
p = 0.174
HR 1.20
(0.61, 2.39);
p = 0.595
Abbreviations: CI confidence interval, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, GOLD Global Initiative for Chronic Obstructive Lung Disease,
HR hazard ratio, ICS inhaled corticosteroid, RR rate ratio. Matched-subgroup population. *Cox regression analysis with ICS use at baseline and matching factors as
covariates. †Poisson regression with ICS use at baseline and matching factors (age, FEV1% predicted, GOLD stage, emphysema diagnosis, and courses of antibiotics)
as covariates. #32 patients treated with FP at baseline received this treatment for non-pulmonary (mostly nasal) indication only; four of these patients had a pneumonia
event during the study. In the “other ICS” group, these numbers were 43 and 11, respectively
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supplement (Additional file 1: Table S2, Figure S1). In
summary, the risk of pneumonia events was increased in
patients with ICS use at baseline as compared with those
without ICS (HR 1.20 [95% CI 1.01, 1.42; p = 0.037]; RR
1.18 [95% CI 0.95, 1.48; p = 0.134]). The proportion of
patients with pneumonia leading to hospitalization was
higher in the ICS subgroup (8.9%) compared with the
no-ICS subgroup (7.4%). Whilst the annual rate of hos-
pitalized pneumonia (RR 1.17 [95% CI 0.89, 1.54; p =
0.251]) supports the decreased time to hospitalized
pneumonia events with ICS use versus no ICS at base-
line (HR 1.22 [95% CI 0.98, 1.52; p = 0.076]), the number
of deaths from pneumonia did not differ by ICS use at
baseline (HR 1.01 [95% CI 0.52, 1.98; p = 0.979]).
Discussion
Despite recommendations for the use of ICS in combin-
ation with long-acting bronchodilators for the manage-
ment of patients with frequent exacerbations [32],
uncertainties about the efficacy and potential side effects
of ICS therapies have led to concerns regarding their use
[4]. In this post hoc analysis of the 4-year UPLIFT® trial,
we assessed whether ICS use, and particularly FP, when
taken long-term in the treatment of COPD was associ-
ated with a higher risk of pneumonia. Our findings indi-
cate that long-term use of FP was associated with a 48%
increased rate of pneumonia compared with other types
of ICS, and a 58% increased risk compared with no ICS
treatment. In this analysis, there was no significant dif-
ference between patients who received other ICS com-
pared with patients who received no ICS, suggesting that
FP may have a stronger association with pneumonia
than alternative ICS therapies. These findings were also
supported by two sensitivity analyses that investigated
the risk of a pneumonia event by ICS treatment at base-
line, and taking switches during the study into account.
In this analysis, the risk of pneumonia (based on time
to first event and annual rate) was higher in patients
treated with FP compared with other ICS or no ICS, and
this was consistent whether patients were receiving
those treatments permanently throughout the study or
at baseline. Our results add to those of a previous retro-
spective post hoc analysis of UPLIFT®, which concluded
that FP usage was associated with excess morbidity (in-
cluding risk of pneumonia and increase in COPD exacer-
bations) compared with other ICS or no ICS [28]. In the
previous analysis, the subgroups were not matched ac-
cording to their baseline characteristics and permanent
users were not analyzed; therefore, our analysis makes it
unlikely that differences between the ICS groups may be
due to different disease severity at baseline.
An increased risk of pneumonia with FP versus other
ICS or no ICS has been reported previously by other
randomized studies of FP-containing regimens in COPD
[5, 6, 11, 18, 20, 28]. A review of 43 randomized con-
trolled studies of COPD treatments found that flutica-
sone (either alone or in combination with long-acting
β2-agonist [LABA] therapy) increased the risk of
non-fatal serious adverse pneumonia events (requiring
hospital admission) compared with placebo or LABA
monotherapy [6]. Furthermore, fluticasone was associ-
ated with a higher risk of any pneumonia event (includ-
ing community-treated cases) compared with the ICS
budesonide, with an odds ratio of 1.86 (95% CI 1.04,
3.34) [6]. A relatively high risk of pneumonia with FP
therapy compared with budesonide use was also re-
ported by a large cohort study of more than 160,000 pa-
tients with COPD over 5 years of follow-up, specifically
with regard to serious events [5]. The 2-year Investigat-
ing New Standards for Prophylaxis in Reduction of
Exacerbations (INSPIRE) and the 3-year Towards a
Revolution in COPD Health (TORCH) trials both stud-
ied high daily doses of FP (1000 μg per day) in COPD
patients [18, 20]. In INSPIRE, the HR for time to first
pneumonia was 1.94 (95% CI 1.19, 3.17) for the salme-
terol/FP combination (SFC) versus tiotropium [20]; in
TORCH, the HRs were 1.64 (95% CI 1.33, 2.02) for SFC
versus placebo, and 1.53 (95% CI 1.24, 1.89) for FP ver-
sus placebo [18]. Additionally, in a meta-analysis of 54
randomized controlled studies including 61,551 patients
with COPD, the two treatments that were shown to in-
crease the risk of pneumonia compared with placebo
were FP and SFC [22].
More recent studies have also looked at the association
of fluticasone furoate (FF) with pneumonia; this is a dif-
ferent salt form compared with FP, with distinct proper-
ties [33]. Data for the association of pneumonia with FF
from recent large-scale studies (the Salford Lung Study,
Table 4 Percentage of patients experiencing pneumonia events,
stratified by treatment at baseline and last visit proximate to event
Treatment
FP Other ICS No ICS
Patients with first pneumonia event (%)
Treatment at baseline 15.5 13.8 12.7
Treatment at last visit before eventa 12.9 10.1 8.6
First hospitalized pneumonia event (%)
Treatment at baseline 10.5 8.5 7.5
Treatment at last visit before eventa 8.3 6.6 5.2
Pneumonia event resulting in death (%)
Treatment at baseline 0.6 1.3 1.1
Treatment at last visit before eventa 0.6 0.9 0.7
Abbreviations: FP fluticasone propionate, ICS inhaled corticosteroid. Patients
were matched at baseline (matched subgroup by baseline ICS use population,
N = 4002). aPercentages are calculated as patients with pneumonia events /
patients taking treatment at any time prior to the event or, in those without
event, at any time during the study
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N = 2799) [34] and the Study to Understand Mortality
and MorbidITy in COPD [SUMMIT], N = 16,485) [35]
are difficult to interpret. The Salford Lung Study did re-
port a trend toward a higher mean number of serious
pneumonia adverse events with FF/vilanterol (FF/VI) in
the subgroup of patients who had not been receiving
ICS at baseline [34]. However, in patients receiving ICS
at study baseline, the study was effectively comparing
FF/VI versus other ICS (including FP), and showed no
notable difference between the two groups. In SUMMIT,
the results were also mixed, with no obvious increase in
pneumonia rates for the comparison of the FF-contain-
ing arms versus placebo; however, compared with the VI
arms, the rates per 100 patient-years were 3.9 for the
FF/VI combination and 4.2 for FF monotherapy, com-
pared with 2.8 for VI monotherapy [35]. A greater risk
of pneumonia with FF/VI compared with VI monother-
apy was also reported previously in an analysis of two
1-year studies of patients with moderate-to-very severe
airflow limitation and at least one COPD exacerbation
in the previous year [21]. Most recently, in the FULFIL
trial, a head-to-head comparison showed that pneumo-
nia was reported in 20/911 (2.2%) patients in the FF arm
compared with 7/899 (0.8%) in the budesonide arm (p <
0.01) [36, 37].
In a nested case-controlled study with a large cohort
of 175,906 patients with COPD, current use of ICS
(within the last 60 days) was associated with a significant
70% increase in the risk of being hospitalized with severe
pneumonia [17]. This effect was even greater with higher
doses of ICS (equivalent to 1000 μg fluticasone per day)
[17]. Although the impact of particular ICS therapies
was not assessed, this suggests that patients with COPD
receiving ICS in general practice should be closely moni-
tored for pneumonia events and treated promptly to
avoid the need for secondary care.
In our post hoc analysis, a higher proportion of pa-
tients on FP were hospitalized with pneumonia events
compared with patients treated with other ICS or no
ICS, and the annual rate of hospitalization was also
highest with FP. The sensitivity analysis by type of ICS
use at baseline supported the higher annual rate of
hospitalization with FP. This suggests that patients with
COPD receiving FP may require particularly careful
surveillance.
With regard to pneumonia events leading to death, the
numbers with FP were somewhat smaller than with
other ICS. However, the overall numbers of fatal pneu-
monia events in UPLIFT® are too small to adequately ad-
dress this topic here.
It is unclear why patients receiving FP may be more
likely to experience pneumonia (including events requir-
ing hospitalization) relative to those receiving alternative
ICS. It has been suggested that the difference between
FP and budesonide is the longer retention of FP in the
airways [38]. FP can persist for hours in the airway lining
fluid, whereas budesonide is absorbed away within mi-
nutes. In this way, FP can suppress the immune system,
enhance susceptibility to respiratory infections, and in-
crease the load of pathogenic microbiome in the airways
and lungs, leading to pneumonia in the weeks following
an unresolved exacerbation [38]. Another potential ex-
planation is due to the dosing of FP. ICS are often pre-
scribed to patients with COPD at high doses, and the
association between pneumonia and ICS use may be
dose-related, with high doses of ICS having the greatest
risk of pneumonia compared with low and medium
doses [19, 39]. As FP is likely to be given at higher doses
than other ICS, this could be one explanation for the re-
sults seen here, although other data have shown that an
increased risk of pneumonia can be associated even with
low doses of ICS [40], and therefore dose may not fully
explain the association with pneumonia.
It has been reported that the risk of pneumonia is in-
creased in patients with more advanced COPD or severe
airflow limitation [41]. Therefore, for the purposes of
our post hoc analysis, patients were matched by baseline
FEV1% predicted and GOLD stage, thus avoiding con-
founding by severity of underlying disease. Just over half
of the patients included in the present analyses had se-
vere (GOLD Stage III) to very severe (GOLD Stage IV)
COPD, similar to the primary study demographic [29].
An observational study of patients hospitalized for pneu-
monia reported that of 4121 community-acquired pneu-
monia episodes, 23.9% occurred in patients with COPD,
and 58% of these patients were GOLD Stage III or IV
[42]. Given the likelihood of an increased risk of pneu-
monia with both the progression of disease and ICS use
(particularly FP, as supported by the current and previ-
ously published analyses of large-scale COPD trials),
physicians need to consider pneumonia as part of the
risk–benefit ratio of ICS use (and in the choice of ICS)
relative to disease severity prior to prescribing [7].
This analysis of UPLIFT® has strengths and limitations.
UPLIFT® provides a large data set over 4 years that en-
ables evaluation of treatment effects on rare adverse
events. Unlike other landmark trials of COPD, patients
were permitted to continue using their background ther-
apy (including ICS) and also have their treatment
adapted, reflecting real-life clinical practice. Information
on the type(s) of ICS was collected at baseline and
throughout the study, allowing comparison of the effects
of different types of ICS on pneumonia risk. Further-
more, the long study duration allowed time for potential
ICS-specific side effects to manifest themselves. How-
ever, the UPLIFT® trial was not designed to study pneu-
monia as a specific event; therefore, it was not
statistically powered to detect differences in pneumonia
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between the subgroups. In addition, since the dosage of
FP or other ICS at baseline and at the end of treatment
was not captured during the UPLIFT® study, and as dos-
age will vary between countries, it was not possible to
evaluate the treatment dose-response. Not all of the
pneumonia events during UPLIFT® were verified by
chest X-ray, although patients with a hospitalization for
suspected pneumonia were likely to have their diagnosis
confirmed radiographically. Furthermore, due to the
overlap in presentation of pneumonia and exacerbations
in a primary care setting, there can be difficulties in dis-
tinguishing between these. Here, this may have led to
biases, particularly as patients were not matched for pre-
vious exacerbation history in this analysis. Additionally,
in this analysis, smoking status was not included in the
matching baseline features, as doing so resulted in a
considerably smaller sample size and there was a differ-
ence in smoking status between subgroups. There was
also a greater proportion of anticholinergic users at
baseline in the FP group than in the no-ICS group. A
pooled safety analysis showed that tiotropium does not
have a significant effect on pneumonia [31], but if tiotro-
pium’s beneficial effect on exacerbations reduced pneu-
monia reporting in the FP group, this would have
attenuated the apparent effect of FP on pneumonia rates.
Finally, it is possible that FP treatment before the study
was a marker of a patient’s sensitivity to pneumonia, and
this could not be balanced by matching the patients.
However, it is difficult to see why this would be different
for other ICS, which showed a smaller risk of pneumo-
nia than FP.
Conclusions
This post hoc analysis of the UPLIFT® trial indicated that
use of FP over 4 years was associated with an increased
risk of pneumonia compared with no ICS treatment or
other types of ICS. This did not appear to be con-
founded by factors associated with ICS treatment (such
as disease severity), as a matched-subgroup analysis was
conducted. In the current analysis, other ICS showed
only numerical increases in pneumonia risk versus no
ICS treatment.
The findings add to the existing evidence regarding
pneumonia risk associated with ICS therapy and, in par-
ticular, long-term FP use in patients with COPD.
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